Key result
Canagliflozin use was not associated with an increased risk of sarcopenia compared with empagliflozin (HR 0.71; 95% CI 0.26-1.91) or other antihyperglycemic agents in patients with type 2 diabetes.
Why the study?
Real-world data were needed to evaluate the incidence and risk of sarcopenia for canagliflozin compared with other antihyperglycemic agents.
Does canagliflozin increase the risk of sarcopenia compared to other antihyperglycemic agents in patients with type 2 diabetes mellitus?
Cohort
Yes
Does canagliflozin increase the risk of sarcopenia compared to other antihyperglycemic agents in patients with type 2 diabetes mellitus?
Real-world data from the US suggests that canagliflozin does not increase the risk of sarcopenia compared to other antihyperglycemic agents in patients with type 2 diabetes.
This is the authors' abstract. We don't add key points for this paper.
Real-world data were analyzed to evaluate the incidence and risk of sarcopenia for canagliflozin compared with other antihyperglycemic agents (AHAs) including dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs), empagliflozin, and dapagliflozin. This retrospective cohort analysis of patients with type 2 diabetes mellitus (T2DM) included new users of canagliflozin or the AHAs (2016 to 2023) in 7 United States healthcare databases. Large-scale regularized regression generated propensity scores (PS) were used for matching and controlling confounding. A conditional Cox proportional hazards model assessed the treatment effect, presented as hazard ratios (HR). A self-controlled case series (SCCS) analysis assessed the incidence rate ratio between exposed and non-exposed periods among canagliflozin users. The PS-matched analyses showed no statistically significant increased risk of sarcopenia with canagliflozin versus any AHA comparator, though confidence intervals (CIs) were wide due to low event rates. The calibrated HRs (95% CI) were 0.71 (0.26, 1.91) for canagliflozin versus empagliflozin, 1.16 (0.28, 4.70) for canagliflozin versus dapagliflozin, 8.79 (0.66, 116.96) for canagliflozin versus GLP-1RAs, and 0.88 (0.26, 2.98) for canagliflozin versus DPP-4 inhibitors. The crude incidence rates of sarcopenia (per 10,000 person-years) varied across databases: canagliflozin (0.0 to 1.0), dapagliflozin (0.4 to 7.9), empagliflozin (0.7 to 3.4), DPP-4 inhibitors (0.4 to 4.8), and GLP-1RAs (0.5 to 3.4). The SCCS analysis indicated an incidence ratio of 0.83 (0.50, 1.37). The incidence rates of sarcopenia were low among patients with T2DM treated with canagliflozin or other comparator AHAs. There is no evidence suggesting an increased risk of sarcopenia associated with canagliflozin compared with other AHAs.
Answers are grounded in this paper and cite their sources.
Canagliflozin shows no excess sarcopenia risk versus empagliflozin in type 2 diabetes; hypothesis-generating and needs prospective validation.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2025) conducted a cohort in type 2 diabetes mellitus (T2DM). canagliflozin vs. other antihyperglycemic agents (empagliflozin, dapagliflozin, GLP-1RAs, DPP-4 inhibitors) was evaluated on sarcopenia (HR 0.71, 95% CI 0.26-1.91). Canagliflozin use was not associated with an increased risk of sarcopenia compared with empagliflozin (HR 0.71; 95% CI 0.26-1.91) or other antihyperglycemic agents in patients with type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: